Adam Koppel
@Bain Capital Life Sciences Investors, Llc
Latest period2024 - Q3ReportedManaged Assets$961.176MTotal holdings24
Assets growth rate5.53%Assets growth rate (2-Q avg)-10.63%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Bain Capital Life Sciences Investors, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 24 positions.
Assets under management
The assets under management (AUM) of Bain Capital Life Sciences Investors, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 961.176M in assets, with a quarterly growth rate of 5.53% and a 2-quarter average growth rate of -10.63%. The portfolio is managed by Adam Koppel, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
NUVLNuvalent Inc
| 28.71% | $275.93M 2.697M shares@ $102.3 avg price | |
NAMSNewamsterdam Pharma Company
| 18.09% | $173.867M 10.474M shares@ $16.61 avg price | |
IRONDisc Medicine Inc
| 9.19% | $88.242M 1.796M shares@ $49.15 avg price | |
DNTHDianthus Therapeutics Inc
| 8.59% | $82.508M 3.013M shares@ $27.39 avg price | |
SVRASavara Inc
| 6.43% | $61.758M 14.565M shares@ $4.25 avg price | |
PHVSPharvaris N V
| 6.37% | $61.179M 3.303M shares@ $18.52 avg price | |
ANNXAnnexon Inc
| 5.21% | $50.023M 8.45M shares@ $5.92 avg price | Increased 0.01% |
SLDBSolid Biosciences Inc
| 2.93% | $28.121M 4.035M shares@ $6.98 avg price | |
TNGXTango Therapeutics Inc
| 2.18% | $20.882M 2.712M shares@ $7.71 avg price | Decreased -6.24% |
KYTXKyverna Therapeutics Inc
| 1.72% | $16.471M 3.368M shares@ $4.89 avg price |